Comparative Pharmacology
Head-to-head clinical analysis: PERCODAN DEMI versus TARGINIQ.
Head-to-head clinical analysis: PERCODAN DEMI versus TARGINIQ.
PERCODAN-DEMI vs TARGINIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full mu-opioid receptor agonist; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.
1 tablet (oxycodone 2.25 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.
None Documented
None Documented
Oxycodone: 3-4 hours; salicylate (aspirin): 2-3 hours at low doses, 15-30 hours at high doses; terminal half-life clinically relevant for dosing interval (q4-6h).
Oxycodone terminal half-life is 3.5-4.0 hours; naloxone half-life is 1-1.5 hours. The prolonged-release formulation yields a longer apparent half-life, supporting twice-daily dosing.
Renal: ~90% (oxycodone: ~60% as metabolites, ~10% unchanged; aspirin: ~80% as salicylates, ~10% unchanged). Biliary/fecal: minor.
Oxycodone is primarily excreted renally as noroxycodone and free oxycodone; naloxone undergoes extensive hepatic metabolism and is excreted renally as naloxone-3-glucuronide. For TARGINIQ, approximately 87% of the dose is eliminated in urine: 19% as unchanged oxycodone, 1% as unchanged naloxone, and the remainder as metabolites. Fecal excretion accounts for ~10%.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination